Suggested remit: To appraise the clinical and cost effectiveness of tafasitamab with lenalidomide followed by tafasitamab monotherapy within its marketing authorisation for treating adults with relapsed or refractory diffuse large B-cell lymphoma.
 
Status In progress
Process STA 2018
ID number 3795

Provisional Schedule

Committee meeting: 1 01 June 2022
Expected publication 10 August 2022

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Incyte Corporation (tafasitamab)
Others Department of Health and Social Care
  NHS England
  NHS Great Yarmouth & Waveney CCG
  NHS Islington CCG
  Welsh Government
Patient carer groups African Caribbean Leukaemia Trust
  Anthony Nolan
  Black Health Agency for Equality
  Blood Cancer UK
  Cancer Black Care
  Cancer Equality
  Cancer52
  DKMS
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Leukaemia Cancer Society
  Leukaemia Care
  Lymphoma Action
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  WMUK
Professional groups Association of Cancer Physicians
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society for Haematology
  British Society of Interventional Radiology
  Cancer Research UK
  Health Lumen
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal college of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
  United Kingdom Cutaneous Lymphoma Group

Commentators

Associated guideline groups National Clinical Guideline Centre
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Accord Healthcare (bendamustine, bleomycin, etoposide, gemcitabine, mitoxantrone, oxaliplatin, prednisolone)
  Advanz Pharma (dexamethasone, prednisolone)
  Allergan (dexamethasone, prednisolone)
  Aspen (chlorambucil, dexamethasone)
  Aspire Pharma (dexamethasone)
  Bausch & Lomb (dexamethasone, prednisolone)
  Baxter Healthcare (cyclophosphamide, mitoxantrone)
  Celgene, a BMS company (lenalidomide)
  Cheplapharm Arzneimittel GmbH (etoposide)
  Consilient Health (dexamethasone)
  Dr Reddy’s Laboratories UK (bendamustine)
  Ethypharm (dexamethasone)
  Glenmark Pharmaceuticals Europe (dexamethasone)
  Hameln Pharma (dexamethasone)
  Hospira UK (gemcitabine, mitoxantrone, oxaliplatin, vincristine)
  Karo Pharma (prednisolone)
  Kent Pharmaceuticals (dexamethasone)
  Kyowa Kirin (bleomycin)
  Logixx Pharma (prednisolone)
  Medac GmBH (etoposide, lomustine, oxaliplatin)
  Napp Pharmaceuticals (rituximab)
  Novartis (dexamethasone)
  Panpharma UK (dexamethasone)
  Pfizer (rituximab)
  Phoenix Labs (prednisolone)
  Ranbaxy (gemcitabine, oxaliplatin)
  Rayner Pharmaceuticals (dexamethasone)
  Roche Products (polatuzumab, rituximab)
  Rosemont (dexamethasone)
  RPH Pharmaceuticals (prednisolone)
  Sandoz (cyclophosphamide, rituximab)
  Sanofi (dexamethasone)
  Seacross pharmaceuticals (bendamustine, oxaliplatin)
  Servier Laboratories (pixantrone)
  Synchrony (dexamethasone)
  Teva UK (dexamethasone)
  Thame Laboratories (dexamethasone)
  Wockhardt UK (dexamethasone, prednisolone)
  Zentiva (bendamustine, prednisolone)
General commentators All Wales Therapeutics & Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Haematological Malignancies Group
  Genomics England
  Institute of Cancer Research
  Leukaemia Busters
  Leukaemia UK
  Lymphoma Research Trust
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
21 September 2021 Invitation to participate
05 January 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-September 2021 when we will write to you about how you can get involved. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
26 August 2020 - 24 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
05 December 2017 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance